Lixte Biotechnology Holdings EBIT

The latest EBIT for LIXT is $-5.1B as of June 2026. That compares with $-3.1M in the prior-year period — down 166145.2% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Lixte Biotechnology Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, LIXT's EBIT moved from $-3.1M to $-5.1B — a 166145.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lixte Biotechnology Holdings's operating scale or balance-sheet position.

Against Healthcare companies, LIXT currently prints $-5.1B for EBIT, while the sector average sits near $23B. That is roughly 122.2% below the sector mean. Large gaps often invite a closer look at Lixte Biotechnology Holdings's growth, margins, and balance sheet.

A EBIT figure of $-5.1B for LIXT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting LIXT's EBIT ($-5.1B), review year-over-year change from $-3.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.